Literature DB >> 32424365

Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis.

Antoine Roquilly1,2,3, Cedric Jacqueline4, Marion Davieau4, Alice Mollé5, Abderrahmane Sadek5,6, Cynthia Fourgeux5, Paul Rooze4,7, Alexis Broquet4, Barbara Misme-Aucouturier4, Tanguy Chaumette4, Mickael Vourc'h4,7, Raphael Cinotti7, Nadege Marec8, Vanessa Gauttier5, Hamish E G McWilliam9,10, Frederic Altare11, Jeremie Poschmann12, Jose A Villadangos13,14, Karim Asehnoune15,16.   

Abstract

Sepsis and trauma cause inflammation and elevated susceptibility to hospital-acquired pneumonia. As phagocytosis by macrophages plays a critical role in the control of bacteria, we investigated the phagocytic activity of macrophages after resolution of inflammation. After resolution of primary pneumonia, murine alveolar macrophages (AMs) exhibited poor phagocytic capacity for several weeks. These paralyzed AMs developed from resident AMs that underwent an epigenetic program of tolerogenic training. Such adaptation was not induced by direct encounter of the pathogen but by secondary immunosuppressive signals established locally upon resolution of primary infection. Signal-regulatory protein α (SIRPα) played a critical role in the establishment of the microenvironment that induced tolerogenic training. In humans with systemic inflammation, AMs and also circulating monocytes still displayed alterations consistent with reprogramming six months after resolution of inflammation. Antibody blockade of SIRPα restored phagocytosis in monocytes of critically ill patients in vitro, which suggests a potential strategy to prevent hospital-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32424365     DOI: 10.1038/s41590-020-0673-x

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  60 in total

Review 1.  The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression.

Authors:  Antoine Roquilly; Jose A Villadangos
Journal:  Mol Immunol       Date:  2015-08-08       Impact factor: 4.407

2.  Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.

Authors:  Karim Asehnoune; Philippe Seguin; Jeremy Allary; Fanny Feuillet; Sigismond Lasocki; Fabrice Cook; Hervé Floch; Russell Chabanne; Thomas Geeraerts; Claire Roger; Pierre F Perrigault; Jean L Hanouz; Anne C Lukaszewicz; Matthieu Biais; Perrine Boucheix; Claire Dahyot-Fizelier; Xavier Capdevila; Pierre J Mahe; Pascale Le Maguet; Catherine Paugam-Burtz; Soizic Gergaud; Benoit Plaud; Jean M Constantin; Yannick Malledant; Laurent Flet; Véronique Sebille; Antoine Roquilly
Journal:  Lancet Respir Med       Date:  2014-07-24       Impact factor: 30.700

3.  Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia.

Authors:  Michael R Eber; Ramanan Laxminarayan; Eli N Perencevich; Anup Malani
Journal:  Arch Intern Med       Date:  2010-02-22

Review 4.  Pneumonia prevention to decrease mortality in intensive care unit: a systematic review and meta-analysis.

Authors:  Antoine Roquilly; Emmanuel Marret; Edward Abraham; Karim Asehnoune
Journal:  Clin Infect Dis       Date:  2014-09-24       Impact factor: 9.079

5.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

Review 6.  Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia.

Authors:  A Roquilly; A Torres; J A Villadangos; M G Netea; R Dickson; B Becher; K Asehnoune
Journal:  Lancet Respir Med       Date:  2019-06-07       Impact factor: 30.700

7.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).

Authors:  Antoni Torres; Michael S Niederman; Jean Chastre; Santiago Ewig; Patricia Fernandez-Vandellos; Hakan Hanberger; Marin Kollef; Gianluigi Li Bassi; Carlos M Luna; Ignacio Martin-Loeches; J Artur Paiva; Robert C Read; David Rigau; Jean François Timsit; Tobias Welte; Richard Wunderink
Journal:  Eur Respir J       Date:  2017-09-10       Impact factor: 16.671

8.  Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis.

Authors:  Maarten Bekaert; Jean-Francois Timsit; Stijn Vansteelandt; Pieter Depuydt; Aurélien Vésin; Maité Garrouste-Orgeas; Johan Decruyenaere; Christophe Clec'h; Elie Azoulay; Dominique Benoit
Journal:  Am J Respir Crit Care Med       Date:  2011-11-15       Impact factor: 21.405

9.  Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis.

Authors:  Lonneke A van Vught; Peter M C Klein Klouwenberg; Cristian Spitoni; Brendon P Scicluna; Maryse A Wiewel; Janneke Horn; Marcus J Schultz; Peter Nürnberg; Marc J M Bonten; Olaf L Cremer; Tom van der Poll
Journal:  JAMA       Date:  2016-04-12       Impact factor: 56.272

Review 10.  Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials.

Authors:  Emmanuel Weiss; Wafa Essaied; Christophe Adrie; Jean-Ralph Zahar; Jean-François Timsit
Journal:  Crit Care       Date:  2017-06-27       Impact factor: 9.097

View more
  45 in total

Review 1.  Does tissue imprinting restrict macrophage plasticity?

Authors:  Martin Guilliams; Freya R Svedberg
Journal:  Nat Immunol       Date:  2021-01-18       Impact factor: 25.606

Review 2.  Trained immunity and host-pathogen interactions.

Authors:  Adeline Peignier; Dane Parker
Journal:  Cell Microbiol       Date:  2020-09-17       Impact factor: 3.715

Review 3.  Pneumonia.

Authors:  Antoni Torres; Catia Cilloniz; Michael S Niederman; Rosario Menéndez; James D Chalmers; Richard G Wunderink; Tom van der Poll
Journal:  Nat Rev Dis Primers       Date:  2021-04-08       Impact factor: 52.329

Review 4.  Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword.

Authors:  Andrew R DiNardo; Mihai G Netea; Daniel M Musher
Journal:  N Engl J Med       Date:  2021-01-21       Impact factor: 91.245

5.  Dying cell-derived SAM switches off inflammation.

Authors:  Roel P H De Maeyer; Derek W Gilroy
Journal:  Nat Metab       Date:  2022-04

6.  Macrophage Responses to Environmental Stimuli During Homeostasis and Disease.

Authors:  Adil Rasheed; Katey J Rayner
Journal:  Endocr Rev       Date:  2021-07-16       Impact factor: 19.871

7.  Biomaterial-based delivery of antimicrobial therapies for the treatment of bacterial infections.

Authors:  Pranav P Kalelkar; Milan Riddick; Andrés J García
Journal:  Nat Rev Mater       Date:  2021-09-15       Impact factor: 66.308

Review 8.  Regulation of myeloid-cell activation.

Authors:  Joseph T Greene; Ben F Brian; S Erandika Senevirathne; Tanya S Freedman
Journal:  Curr Opin Immunol       Date:  2021-10-01       Impact factor: 7.486

9.  Liver-Dependent Lung Remodeling during Systemic Inflammation Shapes Responses to Secondary Infection.

Authors:  Christine V Odom; Yuri Kim; Claire L Burgess; Lillia A Baird; Filiz T Korkmaz; Elim Na; Anukul T Shenoy; Emad I Arafa; TuKiet T Lam; Matthew R Jones; Joseph P Mizgerd; Katrina E Traber; Lee J Quinton
Journal:  J Immunol       Date:  2021-09-01       Impact factor: 5.422

Review 10.  Too young to die? How aging affects cellular innate immune responses to influenza virus and disease severity.

Authors:  Christopher M Harpur; Mélanie A Le Page; Michelle D Tate
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.